GPR143, a novel immunohistochemical marker for renal tumors with FLCN/TSC/MTOR-TFE alterations

This study identifies GPR143 as a novel and sensitive immunohistochemical marker that, when used alongside GPNMB, improves the detection of renal tumors harboring FLCN/TSC/mTOR-TFE pathway alterations.

The Gist

Imagine the human kidney as a bustling city. Sometimes, a specific type of "criminal gang" (a rare kidney cancer called translocation renal cell carcinoma) takes over parts of this city. These gangs are tricky because they wear many different disguises (morphology), making them hard for the police (pathologists) to identify just by looking at them under a microscope.

To catch these criminals, the police usually need a special "Wanted Poster" or a unique ID card (a biomarker) that only these gangs carry.

The Old Problem: A Fuzzy Wanted Poster

For a while, the police used a marker called GPNMB as their main ID card. It worked okay, but it had two big flaws:

1. It was sometimes invisible: Some gang members didn't show the ID clearly (low sensitivity).
2. It was hard to read: Sometimes the ink was smudged, making it hard to tell if the person was guilty or innocent (ambiguous results).

This meant some dangerous criminals were slipping through the net because the police couldn't be 100% sure.

The New Discovery: A Sharper Flashlight

The researchers in this paper decided to go back to the digital archives (cancer databases) to find a better ID card. They were looking for a new marker that was regulated by the same "boss" (MiT transcription factors) that runs these specific kidney cancers.

They found a new candidate called GPR143. Think of GPR143 as a high-tech, glowing flashlight that shines brightly on these specific cancer cells.

How It Works in Practice

The researchers tested this new flashlight on two massive groups of kidney cancer patients (from the TCGA database). Here is what they found:

• The Match: When the "MiT/TSC/FLCN" genetic switch was flipped (meaning the cancer was present), the GPR143 flashlight lit up the cells brightly. It worked just as well as the old GPNMB marker for most cases.
• The Superpower: Here is the best part. In some cases where the old GPNMB marker was faint, missing, or confusing (like a smudged fingerprint), the new GPR143 flashlight was bright and clear.

The Bottom Line

Imagine you are trying to find a specific type of bird in a forest.

• The Old Way: You use a net (GPNMB). It catches most of the birds, but sometimes the birds are too small, or the net has holes, and you miss them.
• The New Way: You use a net and a powerful spotlight (GPR143). Even if the bird is hiding in the shadows where the net can't reach, the spotlight reveals it.

In simple terms: This paper introduces GPR143 as a new, highly effective tool for doctors. It doesn't replace the old tool, but it works alongside it to ensure that no tricky kidney cancer is missed. By using both markers together, doctors can catch more of these specific tumors and diagnose them faster and more accurately.

Technical Summary

Technical Summary: GPR143 as a Novel Immunohistochemical Marker for Renal Tumors with FLCN/TSC/mTOR-TFE Alterations

1. Problem Statement

The diagnosis of MiT/TFE family translocation renal cell carcinoma (tRCC) and related renal neoplasms harboring FLCN, TSC, or mTOR pathway alterations presents significant clinical challenges. These difficulties arise from:

• Morphological Heterogeneity: These tumors exhibit diverse and overlapping histological features, making them hard to distinguish based on morphology alone.
• Lack of Reliable Biomarkers: Current ancillary tests are not universally available, and existing markers have limitations.
• Limitations of GPNMB: While GPNMB has been identified as a diagnostic marker for these tumors, its clinical utility is constrained by suboptimal sensitivity and specificity. Furthermore, interpreting GPNMB immunostaining in ambiguous cases can be difficult, potentially leading to missed diagnoses or false negatives.

2. Methodology

The researchers employed a multi-step approach combining bioinformatics and immunohistochemical validation:

• Bioinformatic Screening: The team analyzed publicly available cancer databases to identify novel biomarkers associated with the FLCN/TSC/mTOR-TFE pathway. They specifically looked for genes regulated by MiT transcription factors.
• Target Identification: This analysis highlighted GPR143 (G protein-coupled receptor 143), a transmembrane protein, as being highly expressed in a specific subset of renal cell carcinomas (RCCs).
• Cohort Analysis: The expression patterns of GPR143 were evaluated in two The Cancer Genome Atlas (TCGA) kidney cancer cohorts to correlate high expression levels with specific genetic alterations (FLCN/TSC/mTOR-TFE).
• Immunohistochemical (IHC) Validation: Tissue samples were subjected to GPR143 immunostaining. The results were compared against:
  • Known cases of tRCC and renal tumors with FLCN/TSC/mTOR alterations.
  • GPNMB immunostaining results to assess concordance and potential advantages.

3. Key Contributions

• Discovery of GPR143: The study identifies GPR143 as a previously underutilized, highly specific transmembrane protein regulated by MiT transcription factors in the context of renal oncology.
• Comparative Analysis: The paper provides a direct comparison between the established marker (GPNMB) and the novel marker (GPR143), highlighting the specific scenarios where GPR143 outperforms GPNMB.
• Surrogate Marker Proposal: It proposes GPR143 as a robust surrogate marker for detecting genetic aberrations in the FLCN/TSC/mTOR-TFE pathway, offering a practical alternative or adjunct to genetic testing.

4. Results

• Expression Correlation: In TCGA cohorts, RCCs with high GPR143 expression were significantly enriched for tumors with FLCN/TSC/mTOR-TFE alterations.
• High Sensitivity: GPR143 immunostaining was positive in the majority of confirmed tRCC cases and renal tumors with the relevant genetic alterations.
• Superiority in Ambiguous Cases: A critical finding was the discordance between the two markers in specific instances. While GPR143 and GPNMB were concordant in most cases, diffuse GPR143 immunostaining was observed in cases where GPNMB labeling was negative or only focal.
• Diagnostic Utility: This suggests that GPR143 can detect tumors that might be missed by GPNMB staining alone, thereby reducing false negatives.

5. Significance

The study establishes GPR143 as a valuable adjunct immunohistochemical marker for renal pathology. Its primary significance lies in:

• Improved Screening Sensitivity: By using GPR143 alongside or in place of GPNMB, pathologists can improve the detection rate of FLCN/TSC/mTOR-TFE altered renal tumors.
• Resolution of Diagnostic Ambiguity: It offers a solution for cases where GPNMB results are equivocal or negative, ensuring that patients with these specific genetic subtypes receive accurate diagnoses.
• Clinical Impact: Accurate identification of these tumors is crucial for prognosis and potential targeted therapy (e.g., mTOR inhibitors), making GPR143 a critical tool for precision medicine in renal oncology.